10-Q quarterly report · filed Nov 10, 2026

Kura Oncology, Inc. (KURA) Q3 2026 10-Q Quarterly Report

Short answer

Kura Oncology, Inc. (KURA) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $23M (up 10.1% year over year) with net income of −$70M.

Q3 2026 key financials · XBRL

Revenue
$23M
+10.1% YoY · +9.4% QoQ
Net income
−$70M
+5.3% YoY · −2.8% QoQ
Operating margin
-326.9%
EPS (diluted)
−$0.78
+8.2% YoY · −1.3% QoQ

Source: XBRL data from the Kura Oncology, Inc. (KURA) Q3 2026 10-Q on SEC EDGAR. USD.

Kura Oncology, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $22.8M, versus $20.8M collaboration revenue last year, with $13.9M KOMZIFTI product revenue
  • Collaboration revenue $8.9M, down $11.8M year over year from $20.8M
  • R&D expenses $66.9M, down from $67.9M, while SG&A declined to $30.2M from $32.8M
  • Cash, cash equivalents and short-term investments $492.1M at September 30, 2026, sufficient to fund operations into 2028
  • Net cash used in operating activities $202.8M, up from $181.3M, while ATM proceeds totaled $31.5M
  • Outlook: R&D and SG&A expected to increase, with additional financing required and Phase 3 topline results anticipated in 2028

Risk Factors

  • Newly added commercialization risk: limited experience marketing KOMZIFTI, triggered by its first commercial launch as the company’s first approved product
  • Most materially updated regulatory risk: FDA post-approval commitments include pediatric, long-term safety, renal/hepatic impairment, drug-interaction and companion-diagnostic studies
  • New compliance exposure: healthcare fraud and abuse laws, including Anti-Kickback Statute, False Claims Act and Sunshine Act requirements
  • Near-term market risk: KOMZIFTI competes with FDA-approved REVUFORJ and established AML therapies
  • Financial risk: continued losses and potential need for substantial additional capital, creating dilution or operating restrictions

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Kura Oncology, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.